Letter to the Editor
Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?

https://doi.org/10.1016/j.ejim.2017.07.033Get rights and content

Section snippets

Acknowledgement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

We thank internal medicine physicians for their help in collecting the clinical data (M.Ebbo, N.Schleinitz, G.Kaplanski, C.Gomez).

References (10)

  • B. Faucher et al.

    Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma

    Eur J Intern Med

    (2010)
  • M. Kuwana et al.

    Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis

    J Clin Invest

    (1993)
  • F. van den Hoogen et al.

    2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

    Arthritis Rheum

    (2013)
  • V. Sobanski et al.

    Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis

    Arthritis Rheumatol Hoboken NJ

    (2014)
  • J.C. Parker et al.

    Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA

    Rheumatol Oxf Engl

    (2008)
There are more references available in the full text version of this article.

Cited by (3)

The authors declare no conflict of interest.

View full text